Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

456335

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what criteria NHS England and NICE will apply when deciding on the commercial agreement to be put in place to provide treatment to patients under the conditional approval route in the new Cancer Drugs Fund.
tabling member printed	Lord Clement-Jones
uin	HL6570
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England has advised that it intends to publish new detailed standard operating procedures for the Cancer Drugs Fund (CDF) by June 2016. These will include any further general details concerning the nature of managed access agreements associated with a drug’s entry into the Fund.</p><p>The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for National Health Service patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of the National Institute for Health and Care Excellence, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL6571 question first answered 14/03/2016 15:27:18 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	3396 label Biography information for Lord Clement-Jones

456336

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what types of commercial agreements NHS England and NICE will be required to consider as part of the conditional approval route in the new Cancer Drugs Fund.
tabling member printed	Lord Clement-Jones
uin	HL6571
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England has advised that it intends to publish new detailed standard operating procedures for the Cancer Drugs Fund (CDF) by June 2016. These will include any further general details concerning the nature of managed access agreements associated with a drug’s entry into the Fund.</p><p>The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for National Health Service patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of the National Institute for Health and Care Excellence, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL6570 question first answered 14/03/2016 15:27:18 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	3396 label Biography information for Lord Clement-Jones

456337

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of NHS England’s and NICE’s capabilities in relation to the commercial negotiations between them and pharmaceutical manufacturers in respect of the conditional approval route under the new Cancer Drugs Fund.
tabling member printed	Lord Clement-Jones
uin	HL6572
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England’s Board agreed, on 25 February 2016, a way forward which will see the proposed new arrangements for the Cancer Drugs Fund (CDF) going live on 1 July 2016</p><p><br> We expect NHS England and the National Institute for Health and Care Excellence (NICE) to work together to ensure that both organisations have the necessary capability and capacity to implement these proposals, including the introduction of a conditional approval route.</p><p> </p><p>The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for NHS patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of NICE, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.</p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 14/03/2016 15:16:31 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	3396 label Biography information for Lord Clement-Jones

456349

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what work NHS England and Monitor are undertaking to develop new payment and incentives mechanisms that drive integrated care for diabetes across primary and secondary care settings; and what is the time frame for any new proposals to be published.
tabling member printed	Lord Harrison
uin	HL6583
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England and Monitor are working closely together to ensure that the payment system supports service developments in the vanguard sites (including those where integrated diabetes care is a focus) as well as monitoring local innovative approaches to supporting integrated care taken by some clinical commissioning groups (CCGs). This is to ensure that the payment system keeps abreast with the development of future service models and is not a barrier to the development of new models of care.</p><p> </p><p>During 2016/17, NHS England will look at the current incentives and funding arrangements for diabetes to see how greater alignment could be achieved between the financial incentives for primary and secondary care.</p><p> </p><p>Information on how much money the National Health Service invested in structured education for diabetes patients is not collected centrally.</p><p> </p><p>Under the Health and Social Care Act (2012), NHS England has a statutory duty to conduct an annual assessment of every CCG. Since April 2013, CCGs have been assessed twice, for the period 2013/14 and for 2014/15.</p><p> </p><p>For 2016/17, NHS England will introduce a new CCG Improvement and Assessment Framework (CCG IAF). This new framework will align with NHS England’s mandate and planning process, with the aim of driving improvements in a number of key areas including the management and care of people with diabetes.</p><p> </p><p> </p><p>NHS England has been working with Diabetes UK on including diabetes indicators in the CCG IAF. The proposed diabetes indicators are:</p><p> </p><p>- the percentage of diabetes patients that have achieved all three of the National Institute for Heath and Care Excellence recommended treatment targets; and</p><p>- newly diagnosed diabetes patients referred to, or attending, a structured education course.</p><p> </p><p>Under the proposals, diabetes will also be one of the six clinical priority areas in the CCG IAF that will be overseen by an independent group.</p><p> </p><p>The CCG IAF proposals are subject to the outcome of an engagement process which closed for comments on February 26 2016. More information can be found at:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/ccg-improvmnt/" target="_blank">https://www.england.nhs.uk/commissioning/ccg-improvmnt/</a></p> answering member printed Lord Prior of Brampton grouped question UIN HL6585 HL6586 question first answered 14/03/2016 15:15:42 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2488 label Biography information for Lord Harrison

456350

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Nurses
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many diabetes specialist nurses are currently employed by (1) each Clinical Commissioning Group area, and (2) each hospital trust, in England.
tabling member printed	Lord Harrison
uin	HL6584
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>The Health and Social Care Information Centre provides information on the number of nursing, midwifery and health visiting staff employed in the National Health Service in England but it does not separately identify diabetes specialist nurses.</p><p> </p><p>It is for local NHS organisations with their knowledge of the healthcare needs of their local population to invest in training for specialist skills and to deploy specialist nurses.</p><p><strong> </strong></p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 14/03/2016 15:28:25 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2488 label Biography information for Lord Harrison

456351

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Health Education
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how much money the NHS invested in ensuring access to and provision of structured education for diabetes patients in (1) 2013, (2) 2014 and (3) 2015, and what percentage those figures represent of total NHS spend on diabetes during each year.
tabling member printed	Lord Harrison
uin	HL6585
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England and Monitor are working closely together to ensure that the payment system supports service developments in the vanguard sites (including those where integrated diabetes care is a focus) as well as monitoring local innovative approaches to supporting integrated care taken by some clinical commissioning groups (CCGs). This is to ensure that the payment system keeps abreast with the development of future service models and is not a barrier to the development of new models of care.</p><p> </p><p>During 2016/17, NHS England will look at the current incentives and funding arrangements for diabetes to see how greater alignment could be achieved between the financial incentives for primary and secondary care.</p><p> </p><p>Information on how much money the National Health Service invested in structured education for diabetes patients is not collected centrally.</p><p> </p><p>Under the Health and Social Care Act (2012), NHS England has a statutory duty to conduct an annual assessment of every CCG. Since April 2013, CCGs have been assessed twice, for the period 2013/14 and for 2014/15.</p><p> </p><p>For 2016/17, NHS England will introduce a new CCG Improvement and Assessment Framework (CCG IAF). This new framework will align with NHS England’s mandate and planning process, with the aim of driving improvements in a number of key areas including the management and care of people with diabetes.</p><p> </p><p> </p><p>NHS England has been working with Diabetes UK on including diabetes indicators in the CCG IAF. The proposed diabetes indicators are:</p><p> </p><p>- the percentage of diabetes patients that have achieved all three of the National Institute for Heath and Care Excellence recommended treatment targets; and</p><p>- newly diagnosed diabetes patients referred to, or attending, a structured education course.</p><p> </p><p>Under the proposals, diabetes will also be one of the six clinical priority areas in the CCG IAF that will be overseen by an independent group.</p><p> </p><p>The CCG IAF proposals are subject to the outcome of an engagement process which closed for comments on February 26 2016. More information can be found at:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/ccg-improvmnt/" target="_blank">https://www.england.nhs.uk/commissioning/ccg-improvmnt/</a></p> answering member printed Lord Prior of Brampton grouped question UIN HL6583 HL6586 question first answered 14/03/2016 15:15:43 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2488 label Biography information for Lord Harrison

456352

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is the current primary performance management mechanism through which NHS England hold Clinical Commissioning Groups to account for achieving progress in diabetes service improvement and quality of care.
tabling member printed	Lord Harrison
uin	HL6586
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England and Monitor are working closely together to ensure that the payment system supports service developments in the vanguard sites (including those where integrated diabetes care is a focus) as well as monitoring local innovative approaches to supporting integrated care taken by some clinical commissioning groups (CCGs). This is to ensure that the payment system keeps abreast with the development of future service models and is not a barrier to the development of new models of care.</p><p> </p><p>During 2016/17, NHS England will look at the current incentives and funding arrangements for diabetes to see how greater alignment could be achieved between the financial incentives for primary and secondary care.</p><p> </p><p>Information on how much money the National Health Service invested in structured education for diabetes patients is not collected centrally.</p><p> </p><p>Under the Health and Social Care Act (2012), NHS England has a statutory duty to conduct an annual assessment of every CCG. Since April 2013, CCGs have been assessed twice, for the period 2013/14 and for 2014/15.</p><p> </p><p>For 2016/17, NHS England will introduce a new CCG Improvement and Assessment Framework (CCG IAF). This new framework will align with NHS England’s mandate and planning process, with the aim of driving improvements in a number of key areas including the management and care of people with diabetes.</p><p> </p><p> </p><p>NHS England has been working with Diabetes UK on including diabetes indicators in the CCG IAF. The proposed diabetes indicators are:</p><p> </p><p>- the percentage of diabetes patients that have achieved all three of the National Institute for Heath and Care Excellence recommended treatment targets; and</p><p>- newly diagnosed diabetes patients referred to, or attending, a structured education course.</p><p> </p><p>Under the proposals, diabetes will also be one of the six clinical priority areas in the CCG IAF that will be overseen by an independent group.</p><p> </p><p>The CCG IAF proposals are subject to the outcome of an engagement process which closed for comments on February 26 2016. More information can be found at:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/ccg-improvmnt/" target="_blank">https://www.england.nhs.uk/commissioning/ccg-improvmnt/</a></p> answering member printed Lord Prior of Brampton grouped question UIN HL6583 HL6585 question first answered 14/03/2016 15:15:43 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2488 label Biography information for Lord Harrison

456353

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Examiners
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 17 December 2015 (HL4371), whether they are now able to publish implementation plans for the roll-out of the system of medical examiners.
tabling member printed	Lord Hunt of Kings Heath
uin	HL6587
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>We remain committed to the principle of medical examiners and will be setting out further information in due course.</p><p><strong> </strong></p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 14/03/2016 15:12:51 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

456354

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Wound Dressings: Procurement
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether, in the light of their review of the cost of wound dressings to the NHS, they will ensure that clinical expertise is a full component part of the process in order to ensure that the outcome is clinically effective as well as cost-effective.
tabling member printed	Lord Hunt of Kings Heath
uin	HL6588
answer	answer is ministerial correction date of answer 10/03/2016 answer text <p>The review of wound dressings by a dedicated working group resulted in the development of a number of clinical specifications for wound care products.</p><p> </p><p>In order to progress this work, from April 2016 a new NHS Clinical Evaluation Team will be put in place. The Clinical Evaluation Team will assess wound care products through a comprehensive evaluation process, which will have extensive engagement with NHS clinical staff. Included in the process will be tissue viability and infection control nurses, clinical procurement specialists, doctors, nurses and midwives along with medicine management practitioners from community trusts.</p><p> </p><p>The project’s remit is to review clinical products to identify those that enable high quality patient care whilst delivering the best outcomes for the NHS. The secondary consideration will be to identify products that could be procured more effectively through combined NHS buying power, to deliver greater overall value for money.</p><p> </p><p>The Clinical Evaluation Team is made up of practising clinicians.</p><p>The project will therefore undertake assessments of the total costs and benefits of any recommendations to the overall NHS.</p><p> </p><p> </p><p> </p> answering member printed Lord Prior of Brampton question first answered 10/03/2016 15:04:20 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

456355

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Wound Dressings:: Supply Chains
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what action they will take to ensure that the NHS Supply Chain wound dressing generics project takes account of evidence comparing the cost of managing unhealed and healed wounds, and of the total cost of wound care in the NHS currently as compared with previous estimates.
tabling member printed	Lord Hunt of Kings Heath
uin	HL6589
answer	answer is ministerial correction date of answer 10/03/2016 answer text <p>The review of wound dressings by a dedicated working group resulted in the development of a number of clinical specifications for wound care products.</p><p> </p><p>In order to progress this work, from April 2016 a new NHS Clinical Evaluation Team will be put in place. The Clinical Evaluation Team will assess wound care products through a comprehensive evaluation process, which will have extensive engagement with NHS clinical staff. Included in the process will be tissue viability and infection control nurses, clinical procurement specialists, doctors, nurses and midwives along with medicine management practitioners from community trusts.</p><p> </p><p>The project’s remit is to review clinical products to identify those that enable high quality patient care whilst delivering the best outcomes for the NHS. The secondary consideration will be to identify products that could be procured more effectively through combined NHS buying power, to deliver greater overall value for money.</p><p> </p><p>The Clinical Evaluation Team is made up of practising clinicians.</p><p>The project will therefore undertake assessments of the total costs and benefits of any recommendations to the overall NHS.</p><p> </p><p> </p><p> </p> answering member printed Lord Prior of Brampton question first answered 10/03/2016 15:05:00 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath